Biogen has completed the acquisition of the clinical-stage gene therapy company Nightstar Therapeutics, according to a press release.
The acquisition adds two mid- to late-stage clinical products — NSR-REP1 for the treatment of choroideremia and NSR-RPGR for the treatment of X-linked retinitis pigmentosa — and preclinical programs to Biogen’s portfolio.
“The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities,” Biogen CEO Michel Vounatsos said in the
Uncategorized